NCT02343952: A trial that was reported late by Nasser Hanna, M.D.
This trial has reported, although it was 73 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02343952 |
|---|---|
| Title | A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179 |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 9, 2015 |
| Completion date | Aug. 10, 2020 |
| Required reporting date | Aug. 10, 2021, midnight |
| Actual reporting date | Oct. 22, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 73 |